[P02BB01, trichlorfon, Metrifonate may increase the neuromuscular blocking activities of Clevidipine.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Clevidipine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Clevidipine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.]
[J01GA01, streptomycin, Clevidipine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Clevidipine may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Clevidipine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01CG01, sulbactam, Clevidipine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The metabolism of Sulfamethoxazole can be decreased when combined with Clevidipine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Clevidipine.]
[N05AL01, sulpiride, Sulpiride may increase the neuromuscular blocking activities of Clevidipine.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Clevidipine.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Azapropazone.]
[N06DA01, tacrine, Tacrine may increase the neuromuscular blocking activities of Clevidipine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Clevidipine.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Clevidipine.]
[R03CC03, terbutaline, Terbutaline may increase the neuromuscular blocking activities of Clevidipine.]
[B01AE07, dabigatran etexilate, Clevidipine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Clevidipine.]
[N07XX06, tetrabenazine, The metabolism of Clevidipine can be decreased when combined with Tetrabenazine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Clevidipine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be decreased when combined with Clevidipine.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Clevidipine.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Clevidipine.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Clevidipine.]
[N05AB08, thioproperazine, The risk or severity of hypotension can be increased when Thioproperazine is combined with Clevidipine.]
[N05AC02, thioridazine, The metabolism of Clevidipine can be decreased when combined with Thioridazine.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Clevidipine.]
[B02AB01, aprotinin, Aprotinin may increase the neuromuscular blocking activities of Clevidipine.]
[G04BE06, moxisylyte, Clevidipine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Clevidipine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Clevidipine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Clevidipine is combined with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01AA12, tobramycin, Clevidipine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Clevidipine.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Tolazoline is combined with Clevidipine.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Clevidipine.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Clevidipine.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Clevidipine.]
[N06AF04, tranylcypromine, The metabolism of Clevidipine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of hypotension can be increased when Trazodone is combined with Clevidipine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Clevidipine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EB04, demecarium, Demecarium may increase the neuromuscular blocking activities of Clevidipine.]
[A16AX12, trientine, Clevidipine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Clevidipine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05AA05, triflupromazine, Triflupromazine may increase the neuromuscular blocking activities of Clevidipine.]
[A03AA05, trimebutine, Clevidipine may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Clevidipine may increase the arrhythmogenic activities of Metipranolol.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Clevidipine.]
[C02BA01, trimethaphan, The serum concentration of Clevidipine can be increased when it is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Clevidipine.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Clevidipine.]
[R06AC04, tripelennamine, The metabolism of Clevidipine can be decreased when combined with Tripelennamine.]
[J01FA08, troleandomycin, The metabolism of Clevidipine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Clevidipine can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the neuromuscular blocking activities of Clevidipine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Clevidipine.]
[L01FX04, ipilimumab, Clevidipine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, Tyrothricin may increase the neuromuscular blocking activities of Clevidipine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Clevidipine.]
[R02AA14, oxyquinoline, Clevidipine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Clevidipine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Clevidipine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Clevidipine can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Clevidipine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Clevidipine.]
[S01AA28, vancomycin, Clevidipine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Clevidipine may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Clevidipine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Clevidipine.]
[N06AX09, viloxazine, The metabolism of Clevidipine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Clevidipine.]
[C04AX07, vincamine, Clevidipine may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Clevidipine.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Clevidipine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Clevidipine.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Clevidipine.]
[N05AF05, zuclopenthixol, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Clevidipine.]
[J05AE02, indinavir, The metabolism of Clevidipine can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Clevidipine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Clevidipine.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B06AC02, icatibant, Clevidipine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Clevidipine.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Clevidipine.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Clevidipine.]
[N05AE04, ziprasidone, The risk or severity of hypotension can be increased when Ziprasidone is combined with Clevidipine.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Clevidipine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Clevidipine.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Clevidipine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Clevidipine.]
[J01DH04, doripenem, Clevidipine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Clevidipine.]
[J02AC03, voriconazole, The metabolism of Clevidipine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Clevidipine may increase the neuromuscular blocking activities of Atracurium.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Clevidipine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Clevidipine.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Clevidipine.]
[B03XA04, peginesatide, Clevidipine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Clevidipine.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A08AA11, lorcaserin, The metabolism of Clevidipine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Clevidipine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Clevidipine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Clevidipine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Clevidipine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Clevidipine.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Clevidipine.]
[A02AA05, magnesium silicate, The risk or severity of hypotension can be increased when Magnesium silicate is combined with Clevidipine.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Clevidipine.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Clevidipine.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Clevidipine.]
[D02BA02, octinoxate, Clevidipine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Clevidipine can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Clevidipine.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Clevidipine.]
[N06DA02, donepezil, Donepezil may increase the neuromuscular blocking activities of Clevidipine.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Clevidipine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Clevidipine.]
[G04BD10, darifenacin, The metabolism of Clevidipine can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Clevidipine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Clevidipine.]
[H01CB05, pasireotide, Clevidipine may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Clevidipine.]
[V08CA11, gadofosveset, Clevidipine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Clevidipine.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Clevidipine.]
[A16AX08, teduglutide, Clevidipine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Clevidipine.]
[C04AX11, bencyclane, Clevidipine may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Clevidipine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Clevidipine.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Clevidipine.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CC09, magnesium orotate, The risk or severity of hypotension can be increased when Magnesium orotate is combined with Clevidipine.]
[A06AX06, tegaserod, The metabolism of Clevidipine can be decreased when combined with Tegaserod.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Clevidipine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Pramlintide.]
[L03AA12, ancestim, Clevidipine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Clevidipine can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Clevidipine.]
[A12CC05, magnesium aspartate, The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Clevidipine.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Clevidipine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Benzydamine.]
[L01EE01, trametinib, Clevidipine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Clevidipine.]
[V09AX05, florbetapir F-18, Clevidipine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Clevidipine.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Clevidipine.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Clevidipine is combined with Riociguat.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Lixisenatide.]
[C02KX04, macitentan, Clevidipine may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Clevidipine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Clevidipine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Clevidipine.]
[J05AP05, simeprevir, The metabolism of Clevidipine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Clevidipine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Clevidipine may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Clevidipine.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Clevidipine.]
[A16AA07, metreleptin, The metabolism of Clevidipine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Clevidipine can be increased when combined with Apremilast.]
[L02BG02, formestane, Clevidipine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, Betaine may increase the neuromuscular blocking activities of Clevidipine.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Clevidipine.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02CC01, bethanidine, Clevidipine may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Clevidipine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Clevidipine may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Clevidipine.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Clevidipine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Clevidipine.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Clevidipine.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Clevidipine.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Clevidipine.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Clevidipine.]
[J01XA05, oritavancin, The metabolism of Clevidipine can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of hypotension can be increased when Acepromazine is combined with Clevidipine.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Clevidipine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Dulaglutide.]
[N04AA02, biperiden, The metabolism of Clevidipine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Clevidipine.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Clevidipine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Clevidipine.]
[S03AA06, gentamicin, Clevidipine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Clevidipine.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Clevidipine.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Clevidipine.]
[B01AF03, edoxaban, Clevidipine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The metabolism of Clevidipine can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Clevidipine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Clevidipine.]
[L01XH03, panobinostat, The metabolism of Clevidipine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01EB17, ivabradine, Clevidipine may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Clevidipine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The risk or severity of hypotension can be increased when Brexpiprazole is combined with Clevidipine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Clevidipine.]
[A04AD14, rolapitant, The metabolism of Clevidipine can be decreased when combined with Rolapitant.]
[A06AD03, magnesium peroxide, The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Clevidipine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Clevidipine.]
[V03AB37, idarucizumab, Clevidipine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Clevidipine.]
[J02AC05, isavuconazole, The metabolism of Clevidipine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Clevidipine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clevidipine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Clevidipine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Clevidipine.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Clevidipine.]
[B01AC27, selexipag, Clevidipine may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Clevidipine.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Clevidipine.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Clevidipine.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Clevidipine.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Clevidipine.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Clevidipine.]
[A02AD05, aluminum magnesium silicate, Clevidipine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Clevidipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Clevidipine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Clevidipine.]
[C07AA19, bupranolol, Clevidipine may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Clevidipine.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Clevidipine.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine.]
[N06DA03, rivastigmine, Rivastigmine may increase the neuromuscular blocking activities of Clevidipine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Clevidipine.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Clevidipine.]
[S01GX07, azelastine, The metabolism of Clevidipine can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Clevidipine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Clevidipine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Clevidipine.]
[L01EF02, ribociclib, The metabolism of Clevidipine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Clevidipine.]
[R03CC12, bambuterol, Bambuterol may increase the neuromuscular blocking activities of Clevidipine.]
[A06AH05, naldemedine, Clevidipine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Clevidipine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may increase the bradycardic activities of Clevidipine.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Benfluorex.]
[S01HA02, benoxinate, The serum concentration of Clevidipine can be increased when it is combined with Oxybuprocaine.]
[R05DB01, benzonatate, The serum concentration of Clevidipine can be increased when it is combined with Benzonatate.]
[P01CA02, benznidazole, Clevidipine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Clevidipine.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Clevidipine can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, Clevidipine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Clevidipine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Clevidipine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Clevidipine.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Clevidipine.]
[J01MA23, delafloxacin, Clevidipine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[D01AC10, bifonazole, The therapeutic efficacy of Bifonazole can be increased when used in combination with Clevidipine.]
[P03AC02, bioallethrin, Clevidipine may increase the arrhythmogenic activities of Bioallethrin.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Clevidipine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Clevidipine.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Clevidipine.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Clevidipine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Clevidipine.]
[C07AB07, bisoprolol, The therapeutic efficacy of Clevidipine can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C07AA17, bopindolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nesiritide is combined with Clevidipine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Clevidipine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Clevidipine.]
[C01AA02, acetyldigoxins, Clevidipine may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Semaglutide.]
[N01BX04, capsaicin, Capsaicin may increase the neuromuscular blocking activities of Clevidipine.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Clevidipine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.]
[L02BB05, apalutamide, The metabolism of Clevidipine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Clevidipine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Clevidipine.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Clevidipine.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Clevidipine.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Clevidipine.]
[L04AA37, baricitinib, Clevidipine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Clevidipine.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01GB14, plazomicin, Clevidipine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Celiprolol may increase the arrhythmogenic activities of Clevidipine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Clevidipine.]
[L01XX62, ivosidenib, The metabolism of Clevidipine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Clevidipine.]
[A16AX14, migalastat, Clevidipine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Clevidipine can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Clevidipine.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Clevidipine.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Clevidipine.]
[N01BA04, chloroprocaine, The serum concentration of Clevidipine can be increased when it is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Clevidipine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Clevidipine.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be decreased when combined with Clevidipine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Clevidipine.]
[L04AA39, emapalumab, The metabolism of Clevidipine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Clevidipine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Clevidipine.]
[C01BG07, cifenline, Clevidipine may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Clevidipine.]
[S01ED05, carteolol, Clevidipine may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Clevidipine.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Clevidipine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Clevidipine.]
[J01FA09, clarithromycin, The metabolism of Clevidipine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Clevidipine may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Clevidipine.]
[N05BA09, clobazam, The metabolism of Clevidipine can be decreased when combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Clevidipine.]
[V03AE07, calcium acetate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Clevidipine.]
[L04AB01, etanercept, The metabolism of Clevidipine can be increased when combined with Etanercept.]
[A12CC06, magnesium lactate, The risk or severity of hypotension can be increased when Magnesium lactate is combined with Clevidipine.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Clevidipine.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Clevidipine.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03BX03, cicletanine, Clevidipine may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Clevidipine.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Clevidipine.]
[N07XX11, pitolisant, The serum concentration of Clevidipine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Clevidipine.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Clevidipine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Clevidipine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The metabolism of Clevidipine can be decreased when combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Clevidipine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Clevidipine.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Clevidipine.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Clevidipine.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Clevidipine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Clevidipine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Clevidipine.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Clevidipine.]
[N03AX25, cenobamate, The serum concentration of Clevidipine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Clevidipine can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Clevidipine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Clevidipine.]
[R06AB02, dexchlorpheniramine, The metabolism of Clevidipine can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Clevidipine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Clevidipine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Clevidipine.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Clevidipine.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Clevidipine.]
[M01AX21, diacetylrhein, The metabolism of Clevidipine can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Clevidipine.]
[H02CA02, osilodrostat, The metabolism of Clevidipine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Clevidipine can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Clevidipine.]
[R02AA03, dichlorobenzyl alcohol, Clevidipine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Clevidipine.]
[N02AA08, dihydrocodeine, The metabolism of Clevidipine can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Clevidipine.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Clevidipine.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Clevidipine.]
[S01AA13, fusidic acid, The metabolism of Clevidipine can be decreased when combined with Fusidic acid.]
[C01BD07, dronedarone, The metabolism of Clevidipine can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, Clevidipine may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Clevidipine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Clevidipine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Clevidipine is combined with Opicapone.]
[G04BD09, trospium, The metabolism of Clevidipine can be decreased when combined with Trospium.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Droxicam.]
[V08CA05, mangafodipir, Clevidipine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Clevidipine.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Clevidipine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Clevidipine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Clevidipine.]
[L04AC19, satralizumab, The serum concentration of Clevidipine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Clevidipine.]
[P01BA01, chloroquine, The metabolism of Clevidipine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The metabolism of Clevidipine can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Clevidipine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Clevidipine.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A11CC05, cholecalciferol, The metabolism of Clevidipine can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Ethenzamide.]
[N06BX18, vinpocetine, Clevidipine may increase the arrhythmogenic activities of Vinpocetine.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Clevidipine.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Clevidipine.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Clevidipine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Clevidipine.]
[M09AA01, hydroquinine, Clevidipine may increase the arrhythmogenic activities of Hydroquinine.]
[M01AX25, chondroitin sulfates, Clevidipine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Clevidipine can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Clevidipine is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Clevidipine.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02BG07, flupirtine, Clevidipine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Clevidipine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Clevidipine.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Clevidipine.]
[L03AB10, peginterferon alfa-2b, The metabolism of Clevidipine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Clevidipine may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The serum concentration of Clevidipine can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Clevidipine.]
[L01XX73, sotorasib, The serum concentration of Clevidipine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Clevidipine.]
[S03AA07, ciprofloxacin, The metabolism of Clevidipine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Clevidipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, Clevidipine may increase the QTc-prolonging activities of Citalopram.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Clevidipine.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Clevidipine is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Clevidipine.]
[R06AA04, clemastine, The metabolism of Clevidipine can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Clevidipine.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Clevidipine.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Clevidipine.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glubionate anhydrous.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Clevidipine.]
[N06AX25, St. John's wort extract, The metabolism of Clevidipine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Clevidipine can be decreased when combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Clevidipine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clevidipine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Clevidipine.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Clevidipine.]
[S01EA04, clonidine, Clonidine may increase the atrioventricular blocking (AV block) activities of Clevidipine.]
[C01EB24, mavacamten, The serum concentration of Clevidipine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Tirzepatide.]
[J02AC06, oteseconazole, The therapeutic efficacy of Oteseconazole can be increased when used in combination with Clevidipine.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Clevidipine.]
[N05AH02, clozapine, The metabolism of Clevidipine can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sotagliflozin.]
[J01GB12, arbekacin, Clevidipine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Clevidipine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The metabolism of Clevidipine can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Clevidipine may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Clevidipine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Proquazone.]
[R05DA04, codeine, The metabolism of Clevidipine can be decreased when combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the neuromuscular blocking activities of Clevidipine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Clevidipine.]
[J01XB01, colistin, Clevidipine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Clevidipine.]
[C01BA13, hydroquinidine, Clevidipine may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The risk or severity of hypotension can be increased when Hydrotalcite is combined with Clevidipine.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Clevidipine.]
[A04AA03, tropisetron, Clevidipine may increase the arrhythmogenic activities of Tropisetron.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Clevidipine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Clevidipine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Clevidipine can be decreased when combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Indobufen.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C05BB03, invert sugar, Clevidipine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V08AB05, iopromide, Clevidipine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Clevidipine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Clevidipine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Clevidipine.]
[H01AX01, pegvisomant, Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Clevidipine.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Clevidipine.]
[J02AC02, itraconazole, The metabolism of Clevidipine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Clevidipine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Clevidipine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Clevidipine.]
[C08CA09, lacidipine, Clevidipine may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Clevidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Clevidipine.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Clevidipine is combined with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.]
[A02AD02, magaldrate, The risk or severity of hypotension can be increased when Magaldrate is combined with Clevidipine.]
[A06AD01, magnesium carbonate, The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Clevidipine.]
[C08CA11, manidipine, Clevidipine may increase the arrhythmogenic activities of Manidipine.]
[C07AA14, mepindolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Mepindolol.]
[R06AD07, mequitazine, The metabolism of Clevidipine can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Clevidipine.]
[C04AX01, cyclandelate, Cyclandelate may increase the arrhythmogenic activities of Clevidipine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Clevidipine may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Clevidipine.]
[N06AX07, minaprine, Minaprine may increase the neuromuscular blocking activities of Clevidipine.]
[S01XA18, cyclosporine, The metabolism of Clevidipine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Clevidipine.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Clevidipine.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Clevidipine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Clevidipine is combined with Moxonidine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Clevidipine.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Clevidipine.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Clevidipine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Clevidipine.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Clevidipine.]
[C02CC04, debrisoquin, The metabolism of Clevidipine can be decreased when combined with Debrisoquine.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Clevidipine.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Clevidipine.]
[N07BB05, nalmefene, Clevidipine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Clevidipine.]
[C07AB12, nebivolol, Nebivolol may increase the arrhythmogenic activities of Clevidipine.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Clevidipine can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Clevidipine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Clevidipine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Clevidipine.]
[M03AC11, cisatracurium, Clevidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AB10, escitalopram, The serum concentration of Clevidipine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Clevidipine can be decreased when combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Clevidipine.]
[N06AA01, desipramine, The metabolism of Clevidipine can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Clevidipine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Clevidipine.]
[S03BA01, dexamethasone, The metabolism of Clevidipine can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Clevidipine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Clevidipine can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Clevidipine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Clevidipine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Clevidipine.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Clevidipine.]
[N06AB05, paroxetine, The metabolism of Clevidipine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.]
[C01DA05, pentaerythritol tetranitrate, Clevidipine may increase the vasodilatory activities of Pentaerythritol tetranitrate.]
[P03AC04, permethrin, Clevidipine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Clevidipine.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Diazoxide is combined with Clevidipine.]
[S02DA04, dibucaine, Cinchocaine may increase the neuromuscular blocking activities of Clevidipine.]
[R05DA08, pholcodine, Clevidipine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Clevidipine.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02DG01, pinacidil, Clevidipine may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Clevidipine may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Clevidipine is combined with Pipamperone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Clevidipine.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Clevidipine.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the neuromuscular blocking activities of Clevidipine.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Clevidipine.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Clevidipine.]
[D07XC04, diflucortolone, Clevidipine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Clevidipine.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Clevidipine.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Clevidipine.]
[C02DB01, dihydralazine, Clevidipine may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Clevidipine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Clevidipine.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Clevidipine.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Clevidipine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Clevidipine.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Clevidipine.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Clevidipine.]
[V03AB09, dimercaprol, Clevidipine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, The metabolism of Clevidipine can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The metabolism of Clevidipine can be decreased when combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Clevidipine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.]
[A03FA02, cisapride, The metabolism of Clevidipine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.]
[S01XA23, sirolimus, Clevidipine may increase the immunosuppressive activities of Sirolimus.]
[N05AL04, remoxipride, The metabolism of Clevidipine can be decreased when combined with Remoxipride.]
[S01AX06, resorcinol, Clevidipine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Clevidipine.]
[N07AA03, distigmine, Distigmine may increase the neuromuscular blocking activities of Clevidipine.]
[S02AA12, rifamycin SV, The metabolism of Clevidipine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Clevidipine can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Clevidipine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Clevidipine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clevidipine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Clevidipine.]
[A04AD12, aprepitant, The metabolism of Clevidipine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Clevidipine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Clevidipine.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Clevidipine.]
[C02KX02, ambrisentan, Clevidipine may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Clevidipine.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Clevidipine.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Clevidipine can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Clevidipine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of hypotension can be increased when Doxepin is combined with Clevidipine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Clevidipine.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Clevidipine.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Clevidipine.]
[N01AB08, sevoflurane, The risk or severity of hypotension can be increased when Sevoflurane is combined with Clevidipine.]
[N05AD08, droperidol, The risk or severity of hypotension can be increased when Droperidol is combined with Clevidipine.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Clevidipine can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Clevidipine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Clevidipine.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Clevidipine.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may increase the neuromuscular blocking activities of Clevidipine.]
[C07AB13, talinolol, Clevidipine may increase the arrhythmogenic activities of Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Clevidipine.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Terazosin is combined with Clevidipine.]
[D01BA02, terbinafine, The metabolism of Clevidipine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Clevidipine may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Clevidipine may increase the arrhythmogenic activities of Tertatolol.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Clevidipine.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.]
[M01AG02, tolfenamic acid, Clevidipine may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Clevidipine.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02CA06, urapidil, The risk or severity of hypotension can be increased when Urapidil is combined with Clevidipine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Clevidipine.]
[S01FB02, ephedrine, The serum concentration of Clevidipine can be increased when it is combined with Ephedrine.]
[S01GX10, epinastine, The metabolism of Clevidipine can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Clevidipine can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, Clevidipine may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Clevidipine may increase the arrhythmogenic activities of Barnidipine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Clevidipine.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Clevidipine.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Clevidipine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Clevidipine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Clevidipine.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Clevidipine.]
[N02CA02, ergotamine, The metabolism of Clevidipine can be decreased when combined with Ergotamine.]
[C01DA13, erythrityl tetranitrate, Clevidipine may increase the vasodilatory activities of Erythrityl tetranitrate.]
[L03AX05, pidotimod, Clevidipine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Clevidipine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Clevidipine.]
[H05BX01, cinacalcet, The metabolism of Clevidipine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Clevidipine.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Clevidipine.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Clevidipine.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Clevidipine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Clevidipine.]
[N04AA05, profenamine, Profenamine may increase the neuromuscular blocking activities of Clevidipine.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Clevidipine.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Clevidipine.]
[S01XA06, ethylmorphine, The metabolism of Clevidipine can be decreased when combined with Ethylmorphine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Clevidipine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Clevidipine.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Clevidipine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.]
[A02BA04, nizatidine, Nizatidine may increase the neuromuscular blocking activities of Clevidipine.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Clevidipine.]
[R06AX12, terfenadine, The metabolism of Clevidipine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Clevidipine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Clevidipine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Clevidipine.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Clevidipine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Clevidipine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Clevidipine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Clevidipine.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Clevidipine.]
[C08EA01, fendiline, Clevidipine may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The metabolism of Clevidipine can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Clevidipine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Clevidipine.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Clevidipine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Clevidipine.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Clevidipine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N07CA03, flunarizine, Flunarizine may increase the arrhythmogenic activities of Clevidipine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Clevidipine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Clevidipine.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AB03, fluoxetine, The serum concentration of Clevidipine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of hypotension can be increased when Flupentixol is combined with Clevidipine.]
[N05AB02, fluphenazine, The metabolism of Clevidipine can be decreased when combined with Fluphenazine.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Clevidipine.]
[N05AG01, fluspirilene, Fluspirilene may increase the arrhythmogenic activities of Clevidipine.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01BC03, tegafur, Clevidipine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, Clevidipine may increase the neuromuscular blocking activities of Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Clevidipine.]
[J05AE10, darunavir, The serum concentration of Clevidipine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Clevidipine.]
[N06DA04, galantamine, Galantamine may increase the neuromuscular blocking activities of Clevidipine.]
[M03AC02, gallamine, Clevidipine may increase the neuromuscular blocking activities of Gallamine.]
[C08DA02, gallopamil, Clevidipine may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Clevidipine.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01XA03, telavancin, Clevidipine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Clevidipine.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Clevidipine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Clevidipine.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Clevidipine may increase the arrhythmogenic activities of Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Clevidipine.]
[N01AH02, alfentanil, Alfentanil may increase the bradycardic activities of Clevidipine.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Clevidipine.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Clevidipine.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Clevidipine.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Clevidipine.]
[N05CM18, dexmedetomidine, The metabolism of Clevidipine can be decreased when combined with Dexmedetomidine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Clevidipine.]
[C05AE01, nitroglycerin, Clevidipine may increase the vasodilatory activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Clevidipine.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Doxazosin is combined with Clevidipine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Clevidipine.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Clevidipine.]
[M01CB04, aurothioglucose, Clevidipine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Clevidipine.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Clevidipine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Clevidipine.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Clevidipine.]
[N05AH04, quetiapine, The risk or severity of hypotension can be increased when Quetiapine is combined with Clevidipine.]
[N06BX13, idebenone, Clevidipine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Clevidipine.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Clevidipine.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Clevidipine.]
[B05CB03, magnesium citrate, The risk or severity of hypotension can be increased when Magnesium citrate is combined with Clevidipine.]
[A12CC03, magnesium gluconate, The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Clevidipine.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Clevidipine.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Clevidipine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Clevidipine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Clevidipine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Clevidipine.]
[C08CA10, nilvadipine, Clevidipine may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the arrhythmogenic activities of Clevidipine.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Clevidipine.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Clevidipine.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypotension can be increased when Propiverine is combined with Clevidipine.]
[P01BA02, hydroxychloroquine, The metabolism of Clevidipine can be decreased when combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Clevidipine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The metabolism of Clevidipine can be decreased when combined with Hydroxyzine.]
[C02AC06, rilmenidine, Clevidipine may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Clevidipine.]
[B05XA08, sodium acetate, Clevidipine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Clevidipine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Clevidipine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Clevidipine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.]
[N06AA02, imipramine, The metabolism of Clevidipine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Clevidipine.]
[R01AD07, tixocortol, Clevidipine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be decreased when combined with Clevidipine.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Indoramin is combined with Clevidipine.]
[A11HA07, inositol, Clevidipine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Clevidipine.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Clevidipine.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Clevidipine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Clevidipine can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Clevidipine.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Clevidipine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Clevidipine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Clevidipine.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Clevidipine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Clevidipine.]
[S01EB07, isoflurophate, Isoflurophate may increase the neuromuscular blocking activities of Clevidipine.]
[N04BX02, entacapone, The metabolism of Clevidipine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Clevidipine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Clevidipine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Isoprenaline may increase the neuromuscular blocking activities of Clevidipine.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, Clevidipine may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Clevidipine may increase the vasodilatory activities of Isosorbide dinitrate.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Clevidipine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The metabolism of Clevidipine can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Clevidipine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Clevidipine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the neuromuscular blocking activities of Clevidipine.]
[C02KD01, ketanserin, Clevidipine may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Clevidipine.]
[J02AB02, ketoconazole, The metabolism of Clevidipine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Clevidipine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of hypotension can be increased when Olanzapine is combined with Clevidipine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Clevidipine.]
[L04AA24, abatacept, The metabolism of Clevidipine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, The metabolism of Clevidipine can be decreased when combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Clevidipine.]
[C07AG01, labetalol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02AA05, deserpidine, Clevidipine may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Clevidipine.]
[N07AA30, ambenonium, Ambenonium may increase the neuromuscular blocking activities of Clevidipine.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Clevidipine.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Clevidipine.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Clevidipine.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Clevidipine is combined with Levodopa.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Clevidipine.]
[C08EX01, lidoflazine, Clevidipine may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, Clevidipine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Clevidipine.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The metabolism of Clevidipine can be decreased when combined with Lisuride.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Clevidipine.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Clevidipine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Clevidipine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Clevidipine.]
[B05XA11, magnesium chloride, The risk or severity of hypotension can be increased when Magnesium chloride is combined with Clevidipine.]
[G04BX01, magnesium hydroxide, The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Clevidipine.]
[A12CC10, magnesium oxide, The risk or severity of hypotension can be increased when Magnesium oxide is combined with Clevidipine.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Clevidipine.]
[L01BA05, pralatrexate, Clevidipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Clevidipine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the neuromuscular blocking activities of Clevidipine.]
[R06AE05, meclizine, The metabolism of Clevidipine can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Clevidipine.]
[C01AA08, medigoxin, Clevidipine may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Clevidipine.]
[P01BC02, mefloquine, Mefloquine may increase the neuromuscular blocking activities of Clevidipine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Clevidipine.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Dalteparin.]
[N05CH01, melatonin, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Melatonin.]
[N06DX01, memantine, Memantine may increase the neuromuscular blocking activities of Clevidipine.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Clevidipine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Clevidipine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Clevidipine.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BX16, tiopronin, Clevidipine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The metabolism of Clevidipine can be decreased when combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of hypotension can be increased when Paliperidone is combined with Clevidipine.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Clevidipine can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, Clevidipine may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Clevidipine.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Clevidipine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Clevidipine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Clevidipine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02BG08, ziconotide, Clevidipine may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Clevidipine.]
[N05AA02, methotrimeprazine, The metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Clevidipine.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Clevidipine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Clevidipine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Clevidipine.]
[G03EK01, methyltestosterone, Clevidipine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Clevidipine.]
[A03FA01, metoclopramide, Metoclopramide may increase the neuromuscular blocking activities of Clevidipine.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Clevidipine.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Clevidipine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Clevidipine.]
[S02AA13, miconazole, The metabolism of Clevidipine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Clevidipine.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Clevidipine.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Clevidipine.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Clevidipine.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Clevidipine.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Clevidipine.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.]
[L01XX23, mitotane, The metabolism of Clevidipine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Clevidipine can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Clevidipine.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Clevidipine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Clevidipine.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Clevidipine can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Clevidipine.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M03AC03, vecuronium, Clevidipine may increase the neuromuscular blocking activities of Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Clevidipine.]
[G04CA04, silodosin, The risk or severity of hypotension can be increased when Silodosin is combined with Clevidipine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Clevidipine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Clevidipine.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Clevidipine.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Clevidipine.]
[J01CF06, nafcillin, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Nafcillin.]
[V03AB15, naloxone, The metabolism of Clevidipine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Clevidipine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Clevidipine.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Clevidipine.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Clevidipine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Clevidipine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Clevidipine.]
[S03AA01, neomycin, Clevidipine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Clevidipine.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Clevidipine.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01EB06, neostigmine, Neostigmine may increase the neuromuscular blocking activities of Clevidipine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Clevidipine.]
[J02AA01, amphotericin B, Clevidipine may decrease the nephrotoxic activities of Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L03AX16, plerixafor, Clevidipine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Clevidipine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Clevidipine can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Clevidipine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Clevidipine.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Clevidipine.]
[C04AE02, nicergoline, The risk or severity of hypotension can be increased when Nicergoline is combined with Clevidipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Clevidipine.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Clevidipine.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Clevidipine.]
[V03AB22, amyl nitrite, Clevidipine may increase the vasodilatory activities of Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Clevidipine.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Clevidipine.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Clevidipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clevidipine.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Clevidipine.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Clevidipine.]
[C02DD01, nitroprusside, Clevidipine may increase the hypotensive activities of Nitroprusside.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Clevidipine.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Clevidipine.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Clevidipine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Clevidipine.]
[G02CA02, nylidrin, Clevidipine may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Clevidipine.]
[L04AC04, rilonacept, The metabolism of Clevidipine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Clevidipine.]
[N02AA02, opium, Clevidipine may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, The risk or severity of hypotension can be increased when Tamsulosin is combined with Clevidipine.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Clevidipine.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Clevidipine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C07AA02, oxprenolol, Oxprenolol may increase the arrhythmogenic activities of Clevidipine.]
[N02AA05, oxycodone, The metabolism of Clevidipine can be decreased when combined with Oxycodone.]
[N02AA11, oxymorphone, The metabolism of Clevidipine can be decreased when combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Clevidipine.]
[N05AH05, asenapine, The risk or severity of hypotension can be increased when Asenapine is combined with Clevidipine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Danaparoid.]
[M03AC01, pancuronium, Pancuronium may increase the neuromuscular blocking activities of Clevidipine.]
[J04AB30, capreomycin, Clevidipine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Clevidipine.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Clevidipine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BD11, fesoterodine, Clevidipine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Penbutolol.]
[N05AG03, penfluridol, Clevidipine may increase the arrhythmogenic activities of Penfluridol.]
[J01CE09, penicillin G procaine, Clevidipine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Clevidipine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Clevidipine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Clevidipine.]
[N05AB03, perphenazine, The metabolism of Clevidipine can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Clevidipine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Clevidipine.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Phenformin.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Clevidipine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Clevidipine.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Clevidipine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Clevidipine.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Phentolamine is combined with Clevidipine.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be decreased when combined with Clevidipine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Clevidipine is combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Clevidipine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Clevidipine.]
[L04AB06, golimumab, The metabolism of Clevidipine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V03AB19, physostigmine, Physostigmine may increase the neuromuscular blocking activities of Clevidipine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Clevidipine.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Clevidipine.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Clevidipine.]
[C07AA03, pindolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Clevidipine.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Clevidipine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Clevidipine can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Clevidipine can be decreased when combined with Pipotiazine.]
[N06BX03, piracetam, Clevidipine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Clevidipine.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of hypotension can be increased when Pizotifen is combined with Clevidipine.]
[J05AG02, delavirdine, The metabolism of Clevidipine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Clevidipine.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Clevidipine.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Clevidipine.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Clevidipine.]
[L04AC08, canakinumab, The metabolism of Clevidipine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Clevidipine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Clevidipine.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Clevidipine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Clevidipine.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Clevidipine.]
[C01BA08, prajmaline, Clevidipine may increase the arrhythmogenic activities of Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Clevidipine.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Clevidipine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01DX02, prenylamine, Prenylamine may increase the arrhythmogenic activities of Clevidipine.]
[P01BA03, primaquine, The metabolism of Clevidipine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Clevidipine can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Clevidipine.]
[S01HA05, procaine, Procaine may increase the neuromuscular blocking activities of Clevidipine.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Clevidipine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Clevidipine.]
[N05AB04, prochlorperazine, The metabolism of Clevidipine can be decreased when combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Clevidipine.]
[N05AA03, promazine, The risk or severity of hypotension can be increased when Promazine is combined with Clevidipine.]
[R06AD02, promethazine, The metabolism of Clevidipine can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Clevidipine.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05AC01, periciazine, The risk or severity of hypotension can be increased when Periciazine is combined with Clevidipine.]
[N05CM06, propiomazine, The risk or severity of hypotension can be increased when Propiomazine is combined with Clevidipine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Clevidipine.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Clevidipine.]
[N02AC04, propoxyphene, The metabolism of Clevidipine can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Clevidipine.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Clevidipine.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Clevidipine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Clevidipine.]
[N07XX07, dalfampridine, Clevidipine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Clevidipine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Clevidipine.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the neuromuscular blocking activities of Clevidipine.]
[R06AC01, pyrilamine, The metabolism of Clevidipine can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Clevidipine.]
[P01BC01, quinine, The metabolism of Clevidipine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Clevidipine can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Clevidipine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Clevidipine can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Clevidipine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Clevidipine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Clevidipine.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Clevidipine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Clevidipine is combined with Obinutuzumab.]
[J01GB08, sisomicin, Clevidipine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Clevidipine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Clevidipine.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Clevidipine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Clevidipine.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA03, choline salicylate, Clevidipine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Clevidipine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Clevidipine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Clevidipine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[V04CH02, indigo carmine, Clevidipine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Clevidipine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium pangamate.]
[P02BB01, trichlorfon, Metrifonate may increase the neuromuscular blocking activities of Clevidipine.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Clevidipine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Clevidipine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.]
[J01GA01, streptomycin, Clevidipine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Clevidipine may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Clevidipine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01CG01, sulbactam, Clevidipine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The metabolism of Sulfamethoxazole can be decreased when combined with Clevidipine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Clevidipine.]
[N05AL01, sulpiride, Sulpiride may increase the neuromuscular blocking activities of Clevidipine.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Clevidipine.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Azapropazone.]
[N06DA01, tacrine, Tacrine may increase the neuromuscular blocking activities of Clevidipine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Clevidipine.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Clevidipine.]
[R03CC03, terbutaline, Terbutaline may increase the neuromuscular blocking activities of Clevidipine.]
[B01AE07, dabigatran etexilate, Clevidipine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Clevidipine.]
[N07XX06, tetrabenazine, The metabolism of Clevidipine can be decreased when combined with Tetrabenazine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Clevidipine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be decreased when combined with Clevidipine.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Clevidipine.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Clevidipine.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Clevidipine.]
[N05AB08, thioproperazine, The risk or severity of hypotension can be increased when Thioproperazine is combined with Clevidipine.]
[N05AC02, thioridazine, The metabolism of Clevidipine can be decreased when combined with Thioridazine.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Clevidipine.]
[B02AB01, aprotinin, Aprotinin may increase the neuromuscular blocking activities of Clevidipine.]
[G04BE06, moxisylyte, Clevidipine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Clevidipine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Clevidipine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Clevidipine is combined with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01AA12, tobramycin, Clevidipine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Clevidipine.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Tolazoline is combined with Clevidipine.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Clevidipine.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Clevidipine.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Clevidipine.]
[N06AF04, tranylcypromine, The metabolism of Clevidipine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of hypotension can be increased when Trazodone is combined with Clevidipine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Clevidipine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EB04, demecarium, Demecarium may increase the neuromuscular blocking activities of Clevidipine.]
[A16AX12, trientine, Clevidipine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Clevidipine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05AA05, triflupromazine, Triflupromazine may increase the neuromuscular blocking activities of Clevidipine.]
[A03AA05, trimebutine, Clevidipine may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Clevidipine may increase the arrhythmogenic activities of Metipranolol.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Clevidipine.]
[C02BA01, trimethaphan, The serum concentration of Clevidipine can be increased when it is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Clevidipine.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Clevidipine.]
[R06AC04, tripelennamine, The metabolism of Clevidipine can be decreased when combined with Tripelennamine.]
[J01FA08, troleandomycin, The metabolism of Clevidipine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Clevidipine can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the neuromuscular blocking activities of Clevidipine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Clevidipine.]
[L01FX04, ipilimumab, Clevidipine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, Tyrothricin may increase the neuromuscular blocking activities of Clevidipine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Clevidipine.]
[R02AA14, oxyquinoline, Clevidipine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Clevidipine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Clevidipine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Clevidipine can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Clevidipine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Clevidipine.]
[S01AA28, vancomycin, Clevidipine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Clevidipine may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Clevidipine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Clevidipine.]
[N06AX09, viloxazine, The metabolism of Clevidipine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Clevidipine.]
[C04AX07, vincamine, Clevidipine may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Clevidipine.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Clevidipine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Clevidipine.]
[S01AA13, fusidic acid, The metabolism of Clevidipine can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Clevidipine.]
[N05AF05, zuclopenthixol, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Clevidipine.]
[J05AE02, indinavir, The metabolism of Clevidipine can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Clevidipine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Clevidipine.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B06AC02, icatibant, Clevidipine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Clevidipine.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Clevidipine.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Clevidipine.]
[N05AE04, ziprasidone, The risk or severity of hypotension can be increased when Ziprasidone is combined with Clevidipine.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Clevidipine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Clevidipine.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Clevidipine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Clevidipine.]
[J01DH04, doripenem, Clevidipine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Clevidipine.]
[J02AC03, voriconazole, The metabolism of Clevidipine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Clevidipine may increase the neuromuscular blocking activities of Atracurium.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Clevidipine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Clevidipine.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Clevidipine.]
[B03XA04, peginesatide, Clevidipine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Clevidipine.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A08AA11, lorcaserin, The metabolism of Clevidipine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Clevidipine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Clevidipine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Clevidipine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Clevidipine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Clevidipine.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Clevidipine.]
[A02AA05, magnesium silicate, The risk or severity of hypotension can be increased when Magnesium silicate is combined with Clevidipine.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Clevidipine.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Clevidipine.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Clevidipine.]
[D02BA02, octinoxate, Clevidipine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Clevidipine can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Clevidipine.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Clevidipine.]
[N06DA02, donepezil, Donepezil may increase the neuromuscular blocking activities of Clevidipine.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Clevidipine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Clevidipine.]
[G04BD10, darifenacin, The metabolism of Clevidipine can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Clevidipine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Clevidipine.]
[H01CB05, pasireotide, Clevidipine may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Clevidipine.]
[V08CA11, gadofosveset, Clevidipine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Clevidipine.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Clevidipine.]
[A16AX08, teduglutide, Clevidipine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Clevidipine.]
[C04AX11, bencyclane, Clevidipine may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Clevidipine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Clevidipine.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Clevidipine.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CC09, magnesium orotate, The risk or severity of hypotension can be increased when Magnesium orotate is combined with Clevidipine.]
[A06AX06, tegaserod, The metabolism of Clevidipine can be decreased when combined with Tegaserod.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Clevidipine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Pramlintide.]
[L03AA12, ancestim, Clevidipine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Clevidipine can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Clevidipine.]
[A12CC05, magnesium aspartate, The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Clevidipine.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Clevidipine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Benzydamine.]
[L01EE01, trametinib, Clevidipine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Clevidipine.]
[V09AX05, florbetapir F-18, Clevidipine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Clevidipine.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Clevidipine.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Clevidipine is combined with Riociguat.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Lixisenatide.]
[C02KX04, macitentan, Clevidipine may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Clevidipine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Clevidipine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Clevidipine.]
[J05AP05, simeprevir, The metabolism of Clevidipine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Clevidipine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Clevidipine may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Clevidipine.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Clevidipine.]
[A16AA07, metreleptin, The metabolism of Clevidipine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Clevidipine can be increased when combined with Apremilast.]
[L02BG02, formestane, Clevidipine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, Betaine may increase the neuromuscular blocking activities of Clevidipine.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Clevidipine.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02CC01, bethanidine, Clevidipine may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Clevidipine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Clevidipine may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Clevidipine.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Clevidipine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Clevidipine.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Clevidipine.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Clevidipine.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Clevidipine.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Clevidipine.]
[J01XA05, oritavancin, The metabolism of Clevidipine can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of hypotension can be increased when Acepromazine is combined with Clevidipine.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Clevidipine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Dulaglutide.]
[N04AA02, biperiden, The metabolism of Clevidipine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Clevidipine.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Clevidipine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Clevidipine.]
[S03AA06, gentamicin, Clevidipine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Clevidipine.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Clevidipine.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Clevidipine.]
[B01AF03, edoxaban, Clevidipine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The metabolism of Clevidipine can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Clevidipine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Clevidipine.]
[L01XH03, panobinostat, The metabolism of Clevidipine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01EB17, ivabradine, Clevidipine may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Clevidipine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The risk or severity of hypotension can be increased when Brexpiprazole is combined with Clevidipine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Clevidipine.]
[A04AD14, rolapitant, The metabolism of Clevidipine can be decreased when combined with Rolapitant.]
[A06AD03, magnesium peroxide, The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Clevidipine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Clevidipine.]
[V03AB37, idarucizumab, Clevidipine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Clevidipine.]
[J02AC05, isavuconazole, The metabolism of Clevidipine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Clevidipine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Clevidipine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Clevidipine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Clevidipine.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Clevidipine.]
[B01AC27, selexipag, Clevidipine may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Clevidipine.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Clevidipine.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Clevidipine.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Clevidipine.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Clevidipine.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Clevidipine.]
[A02AD05, aluminum magnesium silicate, Clevidipine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Clevidipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Clevidipine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Clevidipine.]
[C07AA19, bupranolol, Clevidipine may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Clevidipine.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Clevidipine.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine.]
[N06DA03, rivastigmine, Rivastigmine may increase the neuromuscular blocking activities of Clevidipine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Clevidipine.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Clevidipine.]
[S01GX07, azelastine, The metabolism of Clevidipine can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Clevidipine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Clevidipine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Clevidipine.]
[L01EF02, ribociclib, The metabolism of Clevidipine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Clevidipine.]
[R03CC12, bambuterol, Bambuterol may increase the neuromuscular blocking activities of Clevidipine.]
[A06AH05, naldemedine, Clevidipine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Clevidipine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may increase the bradycardic activities of Clevidipine.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Benfluorex.]
[S01HA02, benoxinate, The serum concentration of Clevidipine can be increased when it is combined with Oxybuprocaine.]
[R05DB01, benzonatate, The serum concentration of Clevidipine can be increased when it is combined with Benzonatate.]
[P01CA02, benznidazole, Clevidipine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Clevidipine.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Clevidipine can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, Clevidipine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Clevidipine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Clevidipine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Clevidipine.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Clevidipine.]
[J01MA23, delafloxacin, Clevidipine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[D01AC10, bifonazole, The therapeutic efficacy of Bifonazole can be increased when used in combination with Clevidipine.]
[P03AC02, bioallethrin, Clevidipine may increase the arrhythmogenic activities of Bioallethrin.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Clevidipine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Clevidipine.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Clevidipine.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Clevidipine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Clevidipine.]
[C07AB07, bisoprolol, The therapeutic efficacy of Clevidipine can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C07AA17, bopindolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nesiritide is combined with Clevidipine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Clevidipine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Clevidipine.]
[C01AA02, acetyldigoxins, Clevidipine may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Semaglutide.]
[N01BX04, capsaicin, Capsaicin may increase the neuromuscular blocking activities of Clevidipine.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Clevidipine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.]
[L02BB05, apalutamide, The metabolism of Clevidipine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Clevidipine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Clevidipine.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Clevidipine.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Clevidipine.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Clevidipine.]
[L04AA37, baricitinib, Clevidipine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Clevidipine.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01GB14, plazomicin, Clevidipine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Celiprolol may increase the arrhythmogenic activities of Clevidipine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Clevidipine.]
[L01XX62, ivosidenib, The metabolism of Clevidipine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Clevidipine.]
[A16AX14, migalastat, Clevidipine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Clevidipine can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Clevidipine.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Clevidipine.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Clevidipine.]
[N01BA04, chloroprocaine, The serum concentration of Clevidipine can be increased when it is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Clevidipine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Clevidipine.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be decreased when combined with Clevidipine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Clevidipine.]
[L04AA39, emapalumab, The metabolism of Clevidipine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Clevidipine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Clevidipine.]
[C01BG07, cifenline, Clevidipine may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Clevidipine.]
[S01ED05, carteolol, Clevidipine may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Clevidipine.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Clevidipine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Clevidipine.]
[J01FA09, clarithromycin, The metabolism of Clevidipine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Clevidipine may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Clevidipine.]
[N05BA09, clobazam, The metabolism of Clevidipine can be decreased when combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Clevidipine.]
[V03AE07, calcium acetate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Clevidipine.]
[L04AB01, etanercept, The metabolism of Clevidipine can be increased when combined with Etanercept.]
[A12CC06, magnesium lactate, The risk or severity of hypotension can be increased when Magnesium lactate is combined with Clevidipine.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Clevidipine.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Clevidipine.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03BX03, cicletanine, Clevidipine may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Clevidipine.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Clevidipine.]
[N07XX11, pitolisant, The serum concentration of Clevidipine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Clevidipine.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Clevidipine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Clevidipine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The metabolism of Clevidipine can be decreased when combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Clevidipine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Clevidipine.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Clevidipine.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Clevidipine.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Clevidipine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Clevidipine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Clevidipine.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Clevidipine.]
[N03AX25, cenobamate, The serum concentration of Clevidipine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Clevidipine can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Clevidipine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Clevidipine.]
[R06AB02, dexchlorpheniramine, The metabolism of Clevidipine can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Clevidipine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Clevidipine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Clevidipine.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Clevidipine.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Clevidipine.]
[M01AX21, diacetylrhein, The metabolism of Clevidipine can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Clevidipine.]
[H02CA02, osilodrostat, The metabolism of Clevidipine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Clevidipine can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Clevidipine.]
[R02AA03, dichlorobenzyl alcohol, Clevidipine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Clevidipine.]
[N02AA08, dihydrocodeine, The metabolism of Clevidipine can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Clevidipine.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Clevidipine.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Clevidipine.]
[J01GB08, sisomicin, Clevidipine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Clevidipine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Clevidipine.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Clevidipine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Clevidipine.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Clevidipine can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, Clevidipine may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Clevidipine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Clevidipine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Clevidipine is combined with Opicapone.]
[G04BD09, trospium, The metabolism of Clevidipine can be decreased when combined with Trospium.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Droxicam.]
[V08CA05, mangafodipir, Clevidipine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Clevidipine.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Clevidipine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Clevidipine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Clevidipine.]
[L04AC19, satralizumab, The serum concentration of Clevidipine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Clevidipine.]
[P01BA01, chloroquine, The metabolism of Clevidipine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The metabolism of Clevidipine can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Clevidipine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Clevidipine.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A11CC05, cholecalciferol, The metabolism of Clevidipine can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Clevidipine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Clevidipine may increase the arrhythmogenic activities of Vinpocetine.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Clevidipine.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Clevidipine.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Clevidipine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Clevidipine.]
[M09AA01, hydroquinine, Clevidipine may increase the arrhythmogenic activities of Hydroquinine.]
[M01AX25, chondroitin sulfates, Clevidipine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Clevidipine can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Clevidipine is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Clevidipine.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02BG07, flupirtine, Clevidipine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Clevidipine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Clevidipine.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Clevidipine.]
[L03AB10, peginterferon alfa-2b, The metabolism of Clevidipine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Clevidipine may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The serum concentration of Clevidipine can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Clevidipine.]
[L01XX73, sotorasib, The serum concentration of Clevidipine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Clevidipine.]
[S03AA07, ciprofloxacin, The metabolism of Clevidipine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Clevidipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, Clevidipine may increase the QTc-prolonging activities of Citalopram.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Clevidipine.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Clevidipine is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Clevidipine.]
[V09AB03, ioflupane I-123, Clevidipine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Clevidipine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Clevidipine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The metabolism of Clevidipine can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Clevidipine.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Clevidipine.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Clevidipine.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glubionate anhydrous.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Clevidipine.]
[N06AX25, St. John's wort extract, The metabolism of Clevidipine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Clevidipine can be decreased when combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Clevidipine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clevidipine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Clevidipine.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Clevidipine.]
[S01EA04, clonidine, Clonidine may increase the atrioventricular blocking (AV block) activities of Clevidipine.]
[C01EB24, mavacamten, The serum concentration of Clevidipine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Tirzepatide.]
[J02AC06, oteseconazole, The therapeutic efficacy of Oteseconazole can be increased when used in combination with Clevidipine.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Clevidipine.]
[N05AH02, clozapine, The metabolism of Clevidipine can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sotagliflozin.]
[J01GB12, arbekacin, Clevidipine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Clevidipine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The metabolism of Clevidipine can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Clevidipine may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Clevidipine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Proquazone.]
[R05DA04, codeine, The metabolism of Clevidipine can be decreased when combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the neuromuscular blocking activities of Clevidipine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Clevidipine.]
[J01XB01, colistin, Clevidipine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Clevidipine.]
[C01BA13, hydroquinidine, Clevidipine may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The risk or severity of hypotension can be increased when Hydrotalcite is combined with Clevidipine.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Clevidipine.]
[A04AA03, tropisetron, Clevidipine may increase the arrhythmogenic activities of Tropisetron.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Clevidipine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Clevidipine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Clevidipine can be decreased when combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Indobufen.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C05BB03, invert sugar, Clevidipine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V08AB05, iopromide, Clevidipine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Clevidipine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Clevidipine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Clevidipine.]
[H01AX01, pegvisomant, Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Clevidipine.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Clevidipine.]
[J02AC02, itraconazole, The metabolism of Clevidipine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Clevidipine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Clevidipine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Clevidipine.]
[C08CA09, lacidipine, Clevidipine may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Clevidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Clevidipine.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Clevidipine is combined with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.]
[A02AD02, magaldrate, The risk or severity of hypotension can be increased when Magaldrate is combined with Clevidipine.]
[A06AD01, magnesium carbonate, The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Clevidipine.]
[C08CA11, manidipine, Clevidipine may increase the arrhythmogenic activities of Manidipine.]
[C07AA14, mepindolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Mepindolol.]
[R06AD07, mequitazine, The metabolism of Clevidipine can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Clevidipine.]
[C04AX01, cyclandelate, Cyclandelate may increase the arrhythmogenic activities of Clevidipine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Clevidipine may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Clevidipine.]
[N06AX07, minaprine, Minaprine may increase the neuromuscular blocking activities of Clevidipine.]
[S01XA18, cyclosporine, The metabolism of Clevidipine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Clevidipine.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Clevidipine.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Clevidipine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Clevidipine is combined with Moxonidine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Clevidipine.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Clevidipine.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Clevidipine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Clevidipine.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Clevidipine.]
[C02CC04, debrisoquin, The metabolism of Clevidipine can be decreased when combined with Debrisoquine.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Clevidipine.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Clevidipine.]
[N07BB05, nalmefene, Clevidipine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Clevidipine.]
[C07AB12, nebivolol, Nebivolol may increase the arrhythmogenic activities of Clevidipine.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Clevidipine can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Clevidipine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Clevidipine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Clevidipine.]
[M03AC11, cisatracurium, Clevidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AB10, escitalopram, The serum concentration of Clevidipine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Clevidipine can be decreased when combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Clevidipine.]
[N06AA01, desipramine, The metabolism of Clevidipine can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Clevidipine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V04CH02, indigo carmine, Clevidipine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Clevidipine.]
[S03BA01, dexamethasone, The metabolism of Clevidipine can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Clevidipine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Clevidipine can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Clevidipine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Clevidipine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Clevidipine.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Clevidipine.]
[N06AB05, paroxetine, The metabolism of Clevidipine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.]
[C01DA05, pentaerythritol tetranitrate, Clevidipine may increase the vasodilatory activities of Pentaerythritol tetranitrate.]
[P03AC04, permethrin, Clevidipine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Clevidipine.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Diazoxide is combined with Clevidipine.]
[S02DA04, dibucaine, Cinchocaine may increase the neuromuscular blocking activities of Clevidipine.]
[R05DA08, pholcodine, Clevidipine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Clevidipine.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02DG01, pinacidil, Clevidipine may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Clevidipine may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Clevidipine is combined with Pipamperone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Clevidipine.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Clevidipine.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the neuromuscular blocking activities of Clevidipine.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Clevidipine.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Clevidipine.]
[D07XC04, diflucortolone, Clevidipine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Clevidipine.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Clevidipine.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Clevidipine.]
[C02DB01, dihydralazine, Clevidipine may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Clevidipine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Clevidipine.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Clevidipine.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Clevidipine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Clevidipine.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Clevidipine.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Clevidipine.]
[V03AB09, dimercaprol, Clevidipine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, The metabolism of Clevidipine can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The metabolism of Clevidipine can be decreased when combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Clevidipine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.]
[A03FA02, cisapride, The metabolism of Clevidipine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.]
[S01XA23, sirolimus, Clevidipine may increase the immunosuppressive activities of Sirolimus.]
[N05AL04, remoxipride, The metabolism of Clevidipine can be decreased when combined with Remoxipride.]
[S01AX06, resorcinol, Clevidipine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Clevidipine.]
[N07AA03, distigmine, Distigmine may increase the neuromuscular blocking activities of Clevidipine.]
[S02AA12, rifamycin SV, The metabolism of Clevidipine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Clevidipine can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Clevidipine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Clevidipine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clevidipine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Clevidipine.]
[A04AD12, aprepitant, The metabolism of Clevidipine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Clevidipine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Clevidipine.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Clevidipine.]
[C02KX02, ambrisentan, Clevidipine may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Clevidipine.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Clevidipine.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Clevidipine can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Clevidipine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of hypotension can be increased when Doxepin is combined with Clevidipine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Clevidipine.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Clevidipine.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Clevidipine.]
[N01AB08, sevoflurane, The risk or severity of hypotension can be increased when Sevoflurane is combined with Clevidipine.]
[N05AD08, droperidol, The risk or severity of hypotension can be increased when Droperidol is combined with Clevidipine.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Clevidipine can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Clevidipine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Clevidipine.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Clevidipine.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may increase the neuromuscular blocking activities of Clevidipine.]
[C07AB13, talinolol, Clevidipine may increase the arrhythmogenic activities of Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Clevidipine.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Terazosin is combined with Clevidipine.]
[D01BA02, terbinafine, The metabolism of Clevidipine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Clevidipine may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Clevidipine may increase the arrhythmogenic activities of Tertatolol.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Clevidipine.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.]
[M01AG02, tolfenamic acid, Clevidipine may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Clevidipine.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02CA06, urapidil, The risk or severity of hypotension can be increased when Urapidil is combined with Clevidipine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Clevidipine.]
[S01FB02, ephedrine, The serum concentration of Clevidipine can be increased when it is combined with Ephedrine.]
[S01GX10, epinastine, The metabolism of Clevidipine can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Clevidipine can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, Clevidipine may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Clevidipine may increase the arrhythmogenic activities of Barnidipine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Clevidipine.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Clevidipine.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Clevidipine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Clevidipine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Clevidipine.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Clevidipine.]
[N02CA02, ergotamine, The metabolism of Clevidipine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Clevidipine.]
[C01DA13, erythrityl tetranitrate, Clevidipine may increase the vasodilatory activities of Erythrityl tetranitrate.]
[L03AX05, pidotimod, Clevidipine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Clevidipine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Clevidipine.]
[H05BX01, cinacalcet, The metabolism of Clevidipine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Clevidipine.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Clevidipine.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Clevidipine.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Clevidipine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Clevidipine.]
[N04AA05, profenamine, Profenamine may increase the neuromuscular blocking activities of Clevidipine.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Clevidipine.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Clevidipine.]
[S01XA06, ethylmorphine, The metabolism of Clevidipine can be decreased when combined with Ethylmorphine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Clevidipine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Clevidipine.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Clevidipine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.]
[A02BA04, nizatidine, Nizatidine may increase the neuromuscular blocking activities of Clevidipine.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Clevidipine.]
[R06AX12, terfenadine, The metabolism of Clevidipine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Clevidipine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Clevidipine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Clevidipine.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Clevidipine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Clevidipine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Clevidipine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Clevidipine.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Clevidipine.]
[C08EA01, fendiline, Clevidipine may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The metabolism of Clevidipine can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Clevidipine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Clevidipine.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Clevidipine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Clevidipine.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Clevidipine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N07CA03, flunarizine, Flunarizine may increase the arrhythmogenic activities of Clevidipine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Clevidipine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Clevidipine.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AB03, fluoxetine, The serum concentration of Clevidipine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of hypotension can be increased when Flupentixol is combined with Clevidipine.]
[N05AB02, fluphenazine, The metabolism of Clevidipine can be decreased when combined with Fluphenazine.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Clevidipine.]
[N05AG01, fluspirilene, Fluspirilene may increase the arrhythmogenic activities of Clevidipine.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L01BC03, tegafur, Clevidipine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, Clevidipine may increase the neuromuscular blocking activities of Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Clevidipine.]
[J05AE10, darunavir, The serum concentration of Clevidipine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Clevidipine.]
[N06DA04, galantamine, Galantamine may increase the neuromuscular blocking activities of Clevidipine.]
[M03AC02, gallamine, Clevidipine may increase the neuromuscular blocking activities of Gallamine.]
[C08DA02, gallopamil, Clevidipine may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Clevidipine.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01XA03, telavancin, Clevidipine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Clevidipine.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Clevidipine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Clevidipine.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Clevidipine may increase the arrhythmogenic activities of Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Clevidipine.]
[N01AH02, alfentanil, Alfentanil may increase the bradycardic activities of Clevidipine.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Clevidipine.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Clevidipine.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Clevidipine.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Clevidipine.]
[N05CM18, dexmedetomidine, The metabolism of Clevidipine can be decreased when combined with Dexmedetomidine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Clevidipine.]
[C05AE01, nitroglycerin, Clevidipine may increase the vasodilatory activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Clevidipine.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Doxazosin is combined with Clevidipine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Clevidipine.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Clevidipine.]
[M01CB04, aurothioglucose, Clevidipine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Clevidipine.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Clevidipine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Clevidipine.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Clevidipine.]
[N05AH04, quetiapine, The risk or severity of hypotension can be increased when Quetiapine is combined with Clevidipine.]
[N06BX13, idebenone, Clevidipine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Clevidipine.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Clevidipine.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Clevidipine.]
[B05CB03, magnesium citrate, The risk or severity of hypotension can be increased when Magnesium citrate is combined with Clevidipine.]
[A12CC03, magnesium gluconate, The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Clevidipine.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Clevidipine.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Clevidipine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Clevidipine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Clevidipine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Clevidipine.]
[C08CA10, nilvadipine, Clevidipine may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the arrhythmogenic activities of Clevidipine.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Clevidipine.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Clevidipine.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypotension can be increased when Propiverine is combined with Clevidipine.]
[P01BA02, hydroxychloroquine, The metabolism of Clevidipine can be decreased when combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Clevidipine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The metabolism of Clevidipine can be decreased when combined with Hydroxyzine.]
[C02AC06, rilmenidine, Clevidipine may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Clevidipine.]
[B05XA08, sodium acetate, Clevidipine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Clevidipine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Clevidipine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Clevidipine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.]
[N06AA02, imipramine, The metabolism of Clevidipine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Clevidipine.]
[R01AD07, tixocortol, Clevidipine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be decreased when combined with Clevidipine.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Indoramin is combined with Clevidipine.]
[A11HA07, inositol, Clevidipine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Clevidipine.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Clevidipine.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Clevidipine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Clevidipine can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Clevidipine.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Clevidipine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Clevidipine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Clevidipine.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Clevidipine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Clevidipine.]
[S01EB07, isoflurophate, Isoflurophate may increase the neuromuscular blocking activities of Clevidipine.]
[N04BX02, entacapone, The metabolism of Clevidipine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Clevidipine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Clevidipine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Isoprenaline may increase the neuromuscular blocking activities of Clevidipine.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, Clevidipine may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Clevidipine may increase the vasodilatory activities of Isosorbide dinitrate.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Clevidipine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The metabolism of Clevidipine can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Clevidipine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Clevidipine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the neuromuscular blocking activities of Clevidipine.]
[C02KD01, ketanserin, Clevidipine may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Clevidipine.]
[J02AB02, ketoconazole, The metabolism of Clevidipine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Clevidipine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of hypotension can be increased when Olanzapine is combined with Clevidipine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Clevidipine.]
[L04AA24, abatacept, The metabolism of Clevidipine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, The metabolism of Clevidipine can be decreased when combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Clevidipine.]
[C07AG01, labetalol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02AA05, deserpidine, Clevidipine may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Clevidipine.]
[N07AA30, ambenonium, Ambenonium may increase the neuromuscular blocking activities of Clevidipine.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Clevidipine.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Clevidipine.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Clevidipine.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Clevidipine is combined with Levodopa.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Clevidipine.]
[C08EX01, lidoflazine, Clevidipine may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, Clevidipine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Clevidipine.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The metabolism of Clevidipine can be decreased when combined with Lisuride.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Clevidipine.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium pangamate.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Clevidipine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Clevidipine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Clevidipine.]
[B05XA11, magnesium chloride, The risk or severity of hypotension can be increased when Magnesium chloride is combined with Clevidipine.]
[G04BX01, magnesium hydroxide, The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Clevidipine.]
[A12CC10, magnesium oxide, The risk or severity of hypotension can be increased when Magnesium oxide is combined with Clevidipine.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Clevidipine.]
[L01BA05, pralatrexate, Clevidipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Clevidipine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the neuromuscular blocking activities of Clevidipine.]
[R06AE05, meclizine, The metabolism of Clevidipine can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Clevidipine.]
[C01AA08, medigoxin, Clevidipine may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Clevidipine.]
[P01BC02, mefloquine, Mefloquine may increase the neuromuscular blocking activities of Clevidipine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Clevidipine.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Dalteparin.]
[N05CH01, melatonin, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Melatonin.]
[N06DX01, memantine, Memantine may increase the neuromuscular blocking activities of Clevidipine.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Clevidipine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Clevidipine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Clevidipine.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BX16, tiopronin, Clevidipine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The metabolism of Clevidipine can be decreased when combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of hypotension can be increased when Paliperidone is combined with Clevidipine.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Clevidipine can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, Clevidipine may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Clevidipine.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Clevidipine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Clevidipine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Clevidipine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02BG08, ziconotide, Clevidipine may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Clevidipine.]
[N05AA02, methotrimeprazine, The metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Clevidipine.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Clevidipine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Clevidipine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Clevidipine.]
[G03EK01, methyltestosterone, Clevidipine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Clevidipine.]
[A03FA01, metoclopramide, Metoclopramide may increase the neuromuscular blocking activities of Clevidipine.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Clevidipine.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Clevidipine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Clevidipine.]
[S02AA13, miconazole, The metabolism of Clevidipine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Clevidipine.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Clevidipine.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Clevidipine.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Clevidipine.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Clevidipine.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Clevidipine.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.]
[L01XX23, mitotane, The metabolism of Clevidipine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Clevidipine can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Clevidipine.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Clevidipine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Clevidipine.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Clevidipine can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Clevidipine.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M03AC03, vecuronium, Clevidipine may increase the neuromuscular blocking activities of Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Clevidipine.]
[G04CA04, silodosin, The risk or severity of hypotension can be increased when Silodosin is combined with Clevidipine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Clevidipine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Clevidipine.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Clevidipine.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Clevidipine.]
[J01CF06, nafcillin, The therapeutic efficacy of Clevidipine can be decreased when used in combination with Nafcillin.]
[V03AB15, naloxone, The metabolism of Clevidipine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Clevidipine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Clevidipine.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Clevidipine.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Clevidipine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Clevidipine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Clevidipine.]
[S03AA01, neomycin, Clevidipine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Clevidipine.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Clevidipine.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[S01EB06, neostigmine, Neostigmine may increase the neuromuscular blocking activities of Clevidipine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Clevidipine.]
[J02AA01, amphotericin B, Clevidipine may decrease the nephrotoxic activities of Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[L03AX16, plerixafor, Clevidipine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Clevidipine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Clevidipine can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Clevidipine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Clevidipine.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Clevidipine.]
[C04AE02, nicergoline, The risk or severity of hypotension can be increased when Nicergoline is combined with Clevidipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Clevidipine.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Clevidipine.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Clevidipine.]
[V03AB22, amyl nitrite, Clevidipine may increase the vasodilatory activities of Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Clevidipine.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Clevidipine.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Clevidipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clevidipine.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Clevidipine.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Clevidipine.]
[C02DD01, nitroprusside, Clevidipine may increase the hypotensive activities of Nitroprusside.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Clevidipine.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Clevidipine.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Clevidipine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Clevidipine.]
[G02CA02, nylidrin, Clevidipine may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Clevidipine.]
[L04AC04, rilonacept, The metabolism of Clevidipine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Clevidipine.]
[N02AA02, opium, Clevidipine may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, The risk or severity of hypotension can be increased when Tamsulosin is combined with Clevidipine.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Clevidipine.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Clevidipine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C07AA02, oxprenolol, Oxprenolol may increase the arrhythmogenic activities of Clevidipine.]
[N02AA05, oxycodone, The metabolism of Clevidipine can be decreased when combined with Oxycodone.]
[N02AA11, oxymorphone, The metabolism of Clevidipine can be decreased when combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Clevidipine.]
[N05AH05, asenapine, The risk or severity of hypotension can be increased when Asenapine is combined with Clevidipine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Danaparoid.]
[M03AC01, pancuronium, Pancuronium may increase the neuromuscular blocking activities of Clevidipine.]
[J04AB30, capreomycin, Clevidipine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Clevidipine.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Clevidipine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[G04BD11, fesoterodine, Clevidipine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Penbutolol.]
[N05AG03, penfluridol, Clevidipine may increase the arrhythmogenic activities of Penfluridol.]
[J01CE09, penicillin G procaine, Clevidipine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Clevidipine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Clevidipine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Clevidipine.]
[N05AB03, perphenazine, The metabolism of Clevidipine can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Clevidipine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Clevidipine.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Phenformin.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Clevidipine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Clevidipine.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Clevidipine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Clevidipine.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Phentolamine is combined with Clevidipine.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be decreased when combined with Clevidipine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Clevidipine is combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Clevidipine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Clevidipine.]
[L04AB06, golimumab, The metabolism of Clevidipine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[V03AB19, physostigmine, Physostigmine may increase the neuromuscular blocking activities of Clevidipine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Clevidipine.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Clevidipine.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Clevidipine.]
[C07AA03, pindolol, The risk or severity of bradycardia can be increased when Clevidipine is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Clevidipine.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Clevidipine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Clevidipine can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Clevidipine can be decreased when combined with Pipotiazine.]
[N06BX03, piracetam, Clevidipine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Clevidipine.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of hypotension can be increased when Pizotifen is combined with Clevidipine.]
[J05AG02, delavirdine, The metabolism of Clevidipine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Clevidipine.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Clevidipine.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Clevidipine.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Clevidipine.]
[L04AC08, canakinumab, The metabolism of Clevidipine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Clevidipine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Clevidipine.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Clevidipine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Clevidipine.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Clevidipine.]
[C01BA08, prajmaline, Clevidipine may increase the arrhythmogenic activities of Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Clevidipine.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Clevidipine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01DX02, prenylamine, Prenylamine may increase the arrhythmogenic activities of Clevidipine.]
[P01BA03, primaquine, The metabolism of Clevidipine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Clevidipine can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Clevidipine.]
[S01HA05, procaine, Procaine may increase the neuromuscular blocking activities of Clevidipine.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Clevidipine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Clevidipine.]
[N05AB04, prochlorperazine, The metabolism of Clevidipine can be decreased when combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Clevidipine.]
[N05AA03, promazine, The risk or severity of hypotension can be increased when Promazine is combined with Clevidipine.]
[R06AD02, promethazine, The metabolism of Clevidipine can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Clevidipine.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N05AC01, periciazine, The risk or severity of hypotension can be increased when Periciazine is combined with Clevidipine.]
[N05CM06, propiomazine, The risk or severity of hypotension can be increased when Propiomazine is combined with Clevidipine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Clevidipine.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Clevidipine.]
[N02AC04, propoxyphene, The metabolism of Clevidipine can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Clevidipine.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Clevidipine.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Clevidipine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Clevidipine.]
[N07XX07, dalfampridine, Clevidipine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Clevidipine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Clevidipine.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the neuromuscular blocking activities of Clevidipine.]
[R06AC01, pyrilamine, The metabolism of Clevidipine can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Clevidipine.]
[P01BC01, quinine, The metabolism of Clevidipine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Clevidipine can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Clevidipine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Clevidipine can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Clevidipine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Clevidipine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Clevidipine.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Clevidipine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Clevidipine is combined with Obinutuzumab.]
